

Real-world effectiveness and safety of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a living systematic review and meta-analysis

Lee B et al. Thorax 2025. doi:10.1136/thorax-2025-223376

Methods



- 5 monthly updates searches
- Ovid Embase, Ovid Medline, and Ovid Global Health
- Eligible studies reporting either effectiveness or safety data for nirsevimab or RSV vaccines in real-world settings



50 studies included



7.6m people included

Effectiveness



Nirsevimab

80.7% (95% CI: 75.7 to 85.7) against RSV-related emergency department visits

80.7% (95% CI: 76.1 to 85.2) against RSV-related hospital admissions

75.6% (95% CI: 63.3 to 87.9) against RSV-related ICU admissions



RSV maternal vaccine

No evidence available

RSV vaccine for older adults

77.9% (95% CI: 73.4 to 82.4) against RSV-related emergency department visits

79.6% (95% CI: 73.8 to 85.3) against RSV-related hospital admissions



Safety

Nirsevimab No related severe adverse events reported

RSV maternal vaccine No related severe adverse events reported

RSV vaccine for older adults <10 Guillain-Barré syndrome cases per million doses

Thorax

thorax.bmj.com

X @ThoraxBMJ



British
Thoracic
Society

BMJ Group